Linked Life Data

19255322

Source:http://linkedlifedata.com/resource/pubmed/id/19255322

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2009-3-31
pubmed:abstractText
To determine the maximum-tolerated radiation-absorbed dose (RAD) to critical organs delivered by yttrium-90 ((90)Y) ibritumomab tiuxetan in combination with high-dose carmustine, etoposide, cytarabine, and melphalan (BEAM) chemotherapy with autologous transplantation.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-10536187, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-10561185, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-10688812, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-11301405, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-11319588, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-11579112, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-12011122, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-12621016, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-15181141, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-15367411, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-15534357, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-15939712, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-16399587, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-17379063, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-17709799, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-17961722, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-17979944, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-18024402, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-18025438, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-1864725, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-18854569, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-7623531, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-7692295, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-7884420, http://linkedlifedata.com/resource/pubmed/commentcorrection/19255322-9779701
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1527-7755
pubmed:author
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1653-9
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:19255322-Humans, pubmed-meshheading:19255322-Aged, pubmed-meshheading:19255322-Female, pubmed-meshheading:19255322-Male, pubmed-meshheading:19255322-Radiotherapy Dosage, pubmed-meshheading:19255322-Podophyllotoxin, pubmed-meshheading:19255322-Bone Marrow Transplantation, pubmed-meshheading:19255322-Adult, pubmed-meshheading:19255322-Antineoplastic Agents, pubmed-meshheading:19255322-Middle Aged, pubmed-meshheading:19255322-Neoplasm Recurrence, Local, pubmed-meshheading:19255322-Melphalan, pubmed-meshheading:19255322-Transplantation, Autologous, pubmed-meshheading:19255322-Cytarabine, pubmed-meshheading:19255322-Combined Modality Therapy, pubmed-meshheading:19255322-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:19255322-Carmustine, pubmed-meshheading:19255322-Maximum Tolerated Dose
More...